psoriasis

pivot change turnaround direction walk away
Biotech

Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback, prompting the French drugmaker to pull back from monotherapy plans.
Nick Paul Taylor Apr 24, 2025 4:46am
scrabble tiles spelling out psoriasis

J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu

Mar 10, 2025 7:30am
decision path change of plans arrows business decision

BMS backs out of Dupixent fight, axing asset despite phase 3 win

Feb 7, 2025 6:26am
Illustration connected puzzle pieces with the acronym MA

AbbVie acquires oral peptide biotech Nimble for $200M

Dec 13, 2024 10:38am
On target clinical trial success bullseye score

J&J, Protagonist's oral psoriasis prospect scores in phase 3s

Nov 19, 2024 11:44am
decision path change of plans arrows business decision

Lilly changes lead psoriasis program from $2.4B Dice buyout

Oct 30, 2024 10:00am